Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07522645 · ClinicalTrials.gov registry record · NA
Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Disease
A NA study, sponsored by Kaiser Permanente.
- Active
- Registry status
- NA
- Development phase
- 22,000
- Enrollment target
NCT07522645: Active NA study, sponsored by Kaiser Permanente.
NCT07522645 is a NA study that is active but no longer recruiting, run by Kaiser Permanente. The registered enrollment target is 22,000 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1468% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07522645, a NA study, is active but no longer recruiting, sponsored by Kaiser Permanente.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 22,000 participants
- Enrollment target
Study Summary
The goal of the ADHERE-ASCVD study is to evaluate and optimize patient-facing messaging strategies to improve statin refill and adherence among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes. The main questions it aims to answer are: 1. Do different outreach methods (such as text messages, secure portal messages, or email) increase short-term statin refill compared to usual care? 2. Among patients who do not initially refill their prescription, does changing the outreach method improve refill rates? The team with operational partners will evaluate the comparitive effectivessness of multiple messaging strategies delivered through existing health system communication channels, including SMS (text messaging), secure patient portal messages, non-secure email, and usual care (no additional outreach). Participants * Receive an initial outreach message encouraging statin refill (or usual care) Be monitored for statin refill within 14 days * Potentially receive a second outreach message using the same or a different communication method if they do not initially refill their prescription * Have their medication refill patterns tracked over time, including longer-term adherence outcomes
Primary Outcome
Proportion of participants who refill a statin prescription following message delivery (first-stage intervention) or, among non-responders, following second-stage messaging. Refill status will be determined using pharmacy dispensing records.
Interventions
- BEHAVIORAL SMS (Initial Outreach)
- BEHAVIORAL Secure Portal Message (Initial Outreach)
- BEHAVIORAL Non-secure Email (Initial Outreach)
- BEHAVIORAL SMS (Follow-up for Non-responders)
- BEHAVIORAL Secure Portal Message (Follow-up for Non-responders)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22,000 participants |
| Start Date | 2026-04-14 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What the registry record for NCT07522645 still lists
NCT07522645 is an interventional study that assigns participants to a tested intervention. Its 22,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1468% higher).
The record links to 0 conditions, and to 5 interventions - of which SMS (Initial Outreach) is the first listed.
NCT07522645 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07522645 about?
NCT07522645 is a clinical study titled "Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Disease". The goal of the ADHERE-ASCVD study is to evaluate and optimize patient-facing messaging strategies to improve statin refill and adherence among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes. The main questions it aims to answer are: 1. Do different outreach methods (such a...
What is the current status of trial NCT07522645?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 22,000 participants. The study started on 2026-04-14. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT07522645?
The interventions under investigation include: SMS (Initial Outreach) (BEHAVIORAL), Secure Portal Message (Initial Outreach) (BEHAVIORAL), Non-secure Email (Initial Outreach) (BEHAVIORAL), SMS (Follow-up for Non-responders) (BEHAVIORAL), Secure Portal Message (Follow-up for Non-responders) (BEHAVIORAL).
Who is sponsoring clinical trial NCT07522645?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07522645's enrollment target sits among peer trials
22,000 10th of 2000 higher than 1,991 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05832307 · 22,000 participants · NA
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
- NCT05488080 · 22,032 participants · NA
PAINED: Project Addressing INequities in the Emergency Department
- NCT07413211 · 22,068 participants
Genetic Developmental and Epileptic Encephalopathy Natural History Study for Clinical Trial Readiness
- NCT06486688 · 22,320 participants · NA
Centralized Virtual SBIRT for Pediatric Primary Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI